Anavex Life Sciences Corp (AVXL)

NASDAQ
9.18
-0.16(-1.71%)
Pre Market
9.18
0.00(0.00%)
- Real-time Data
  • Volume:
    864,264
  • Day's Range:
    8.91 - 9.37
  • 52 wk Range:
    7.13 - 23.73

AVXL Overview

Prev. Close
9.34
Day's Range
8.91-9.37
Revenue
-
Open
9.28
52 wk Range
7.13-23.73
EPS
-0.595
Volume
864,264
Market Cap
715.52M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
780,667
P/E Ratio
-15.56
Beta
0.815
1-Year Change
-51.01%
Shares Outstanding
77,942,815
Next Earnings Date
Dec 12, 2022
What is your sentiment on Anavex Life Sciences?
or
Market is currently closed. Voting is open during market hours.

Anavex Life Sciences Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Anavex Life Sciences Corp Analysis

Anavex Life Sciences Corp Company Profile

Anavex Life Sciences Corp Company Profile

Employees
20

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.

Read More

Analyst Price Target

Average35.33 (+284.89% Upside)
High42
Low16
Price9.18
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellNeutral
Technical IndicatorsStrong BuyStrong BuySellStrong SellStrong Sell
SummaryStrong BuyStrong BuySellStrong SellSell
  • Rumor today, that $AVXL is going to verify new joint venture discussions with Roche as early as next week.
    0
    • https://www.reddit.com/r/biotechnology/comments/oawn39/avxl_anavex_273_a_potential_blockbuster_drug_in/?utm_source=share&utm_medium=web2x&context=3
      0
      • The Upside for Biogen Is Absolutely Wild
        1
        • They just valued their own stock @ $21
          2
          • It will go up to $29
            1
            • When will this shoot up again? Not complaining
              0
              • Go buy Ehang!! ********
                0
                • The upcoming revenues are going to explode
                  0
                  • how come it's a sell now on hourly?
                    0
                    • how come it's a sell now on hourly?
                      0